If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
Former Idun Management team to expand efforts in liver disease and oncology SAN DIEGO, July Thirty (HSMN NewsFeed) — Conatus Pharmaceuticals Inc. announced today that Conatus acquired the Idun Pharmaceuticals subsidiary of Pfizer Inc. Financial terms w…
Biopharmaceuticals, Mergers & Acquisitions
Conatus Pharmaceuticals, Idun Pharmaceuticals, Pfizer
Posts from ‘July, 2010’
Conatus Pharmaceuticals Acquires Pfizer’s Idun Subsidiary
ZOLL Propaq MD Monitor/Defibrillator Granted 510(k) Clearance by U.S. Food and Drug Administration
New Ultra-Rugged Device Designed Tough for Military and Air Pathology Operations CHELMSFORD, Mass.–(HSMN NewsFeed)–ZOLL Clinical Corporation (NasdaqGS: ZOLL ), a manufacturer of pharmaceutical devices and related software solutions, announced today that it has …
Devices, Monitoring, FDA
ZOLL Clinical, Propaq MD
Hotspur Technologies Receives FDA 510(k) Clearance for First Three Product Lines Based on the Company’s Unique Technology
Improve Efficiency of Treatments to Restore Bloodflow in Dialysis Grafts and Blocked Arteries MOUNTAIN VIEW, Calif., July Thirty (HSMN NewsFeed) — Hotspur Technologies, Inc. announced today that it has received FDA clearance for the first 3 commercia…
Devices, FDA
Hotspur Technologies, IQCath, GPSCath, The Keeper
Smith and Nephew Given Right to Appeal in Patent Litigation in the United Kingdom - Sales of RENASYS Product Range in UK Continues
HULL, England, July 30 (HSMN NewsFeed) — The Advanced Wound Management division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew plc. (LSE: SN; NYSE: SNN) notes the finding of the Patents Court of the High Court of Justice of England and Wales in…
Devices, Wound Care, Litigation
Smith & Nephew, Kinetic Concepts, Negative Pressure Wound Therapy
Stellar Pharmaceuticals Inc. Signs Agreement for Distribution and Sale of Uracyst(R) in Spain
Continued Expansion of Stellar’s Global Strategy LONDON, ONTARIO July 30, –(HSMN NewsFeed) - Stellar Pharmaceuticals Inc. ("Stellar") (OTC.BB:SLXCF ), a Canadian clinical developer and marketer of high quality, cost-effective products f…
Biopharmaceuticals, Distribution
Stellar Pharmaceuticals, Laboratorios Inibsa, Uracyst
Eisai Inc. and Pfizer Inc Announce U.S. FDA Approval for New Higher-Dose Aricept(R) (donepezil HCl) 23 mg Tablet for the Treatment of Moderate-to-Severe Alzheimer’s Disease
Aricept available in 5 mg, 10 mg and 23 mg doses WOODCLIFF LAKE, N.J. & NEW YORK–(HSMN NewsFeed)–Eisai Inc. and Pfizer Inc [NYSE: PFE] announced today that the U.S. Food and Drug Administration (FDA) approved a new once-daily, higher-dose Aricept (do…
Biopharmaceuticals, Neurology, FDA
Eisai, Pfizer, Aricept, donepezil, Alzheimer’s Disease
ABRAXANE(R) Approved for Marketing in Japan for Breast Cancer
Product Launch Planned for September; ABRAXANE Now Approved in 40 Countries LOS ANGELES–(HSMN NewsFeed)–Abraxis BioScience, Inc. (NASDAQ:ABII ), a fully integrated, global biotechnology company, today announced that Taiho Clinical Co., Ltd. has …
Biopharmaceuticals, Oncology, Regulatory
Abraxis BioScience, Taiho Medical, ABRAXANE, breast cancer
Vermillion Announces Relocation of Corporate Offices to Austin, Texas
FREMONT, Calif., July 23 (HSMN NewsFeed) — Vermillion, Inc. (Nasdaq:VRML ), a molecular diagnostics company, today announced that it is relocating its corporate headquarters from Fremont, California to Austin, Texas. Vermillion has executed a two-year …
Diagnostics
Vermillion
Emisphere Provides an Update on Osteoarthritis Phase III Study With Oral Calcitonin
CEDAR KNOLLS, N.J., July 23, 2010 –(HSMN NewsFeed) — Emisphere Technologies, Inc. (OTCBB:EMIS ) today announced that Novartis Pharma AG and its license senior partner Nordic Bioscience a/s (the "Sponsor") have reported the following in connection with…
Biopharmaceuticals
Emisphere Technologies, Novartis Pharma AG, Nordic Bioscience, calcitonin
Horizon Pharma, Inc. Announces Results of Phase 3 Study of LODOTRA(R) Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis
Results published in July Issue of Annals of Rheumatic Diseases NORTHBROOK, Ill., July 23 (HSMN NewsFeed) — Horizon Pharmaceutical, Inc. announced today the results from the extended open label portion of The Circadian Administration of Prednisone in Rheumat…
Biopharmaceuticals
Horizon Pharma, LODOTRA, Rheumatoid Arthritis
